Woodline Partners’s bluebird bio BLUE Stock Holding History

Woodline Partners’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-48,467	Closed	-$954K	–	608
2024 Q2	$954K	Sell	48,467 -291	-0.6%	-$5.83K	0.01%	465
2024 Q1	$1.25M	Buy	48,758 +23,751	+95%	+$609K	0.01%	449
2023 Q4	$690K	Sell	25,007 -111,430	-82%	-$6.79M	0.01%	414
2023 Q3	$8.3M	Buy	136,437 +97,292	+249%	+$6.83M	0.1%	245
2023 Q2	$2.58M	Sell	39,145 -251	-0.6%	-$18.4K	0.03%	397
2023 Q1	$2.51M	Sell	39,396 -25,139	-39%	-$2.87M	0.03%	394
2022 Q4	$8.93M	Buy	64,535 +7,607	+13%	+$1.07M	0.12%	231
2022 Q3	$7.21M	Buy	+56,928	New	+$6.44M	0.1%	240
2021 Q3	–	Sell	-7,947	Closed	-$3.29M	–	685
2021 Q2	$3.29M	Buy	7,947 +5,284	+198%	+$2.09M	0.06%	283
2021 Q1	$1.04M	Buy	+2,663	New	+$1.31M	0.02%	361

Other funds holding BLUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Woodline Partners's BLUE Position: Q3 2024 in Review

Woodline Partners sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 48,467 shares — an estimated $954K sold.

Woodline Partners first reported a position in BLUE in Q1 2021 and held it in 10 quarters. The position peaked at $8.93M in Q4 2022. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

Woodline Partners reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
Woodline Partners sold 48,467 bluebird bio shares in Q3 2024, an estimated $954K.
Woodline Partners first reported a position in bluebird bio in Q1 2021 and held it in 10 quarters.
Woodline Partners's bluebird bio position peaked at $8.93M in Q4 2022.
140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.